Search Results - Ochenduszko, Sebastian
- Showing 1 - 9 results of 9
-
1
-
2
Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study by Ochenduszko, Sebastian, Puskulluoglu, Mirosława, Konopka, Kamil, Fijorek, Kamil, Slowik, Agnieszka Julia, Pędziwiatr, Michał, Budzyński, Andrzej
Published 2017Text -
3
Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients by Konopka, Kamil, Micek, Agnieszka, Ochenduszko, Sebastian, Streb, Joanna, Potocki, Paweł, Kwinta, Łukasz, Wysocki, Piotr J.
Published 2021Text -
4
Main influencing factors and health-related quality of life issues in patients with oesophago-gastric cancer – as measured by EORTC tools by Tomaszewski, Krzysztof A., Püsküllüoğlu, Mirosława, Biesiada, Katarzyna, Bochenek, Justyna, Ochenduszko, Sebastian, Tomaszewska, Iwona M., Krzemieniecki, Krzysztof
Published 2013Text -
5
Pilot Testing and Preliminary Psychometric Validation of the Polish Translation of the EORTC INFO25 Questionnaire: Validation of the Polish version of INFO25—pilot study by Püsküllüoğlu, Mirosława, Tomaszewski, Krzysztof A., Zygulska, Aneta L., Ochenduszko, Sebastian, Streb, Joanna, Tomaszewska, Iwona M., Krzemieniecki, Krzysztof
Published 2013Text -
6
Enhanced recovery (ERAS) protocol in patients undergoing laparoscopic total gastrectomy by Pędziwiatr, Michał, Matłok, Maciej, Kisialeuski, Mikhail, Major, Piotr, Migaczewski, Marcin, Budzyński, Piotr, Ochenduszko, Sebastian, Rembiasz, Kazimierz, Budzyński, Andrzej
Published 2014Text -
7
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric... by Ochenduszko, Sebastian, Puskulluoglu, Miroslawa, Konopka, Kamil, Fijorek, Kamil, Urbanczyk, Katarzyna, Budzynski, Andrzej, Matlok, Maciej, Lazar, Agata, Sinczak-Kuta, Anna, Pedziwiatr, Michal, Krzemieniecki, Krzysztof
Published 2015Text -
8
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice by Álamo, Mª del Carmen, Ochenduszko, Sebastian, Crespo, Guillermo, Corral, Mónica, Oramas, Juana, Sancho, Pilar, Medina, Javier, Garicano, Fernando, López, Pedro, Campos Balea, Begoña, Rodríguez Garzotto, Analia, Muñoz-Couselo, Eva
Published 2021Text -
9
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial by Gonzalez-Cao, Maria, Mayo de las Casas, Clara, Oramas, Juana, Berciano-Guerrero, Miguel A., de la Cruz, Luis, Cerezuela, Pablo, Arance, Ana, Muñoz-Couselo, Eva, Espinosa, Enrique, Puertolas, Teresa, Diaz Beveridge, Roberto, Ochenduszko, Sebastian, Villanueva, Maria-Jose, Basterretxea, Laura, Bellido, Lorena, Rodriguez, Delvys, Campos, Begoña, Montagut, Clara, Drozdowskyj, Ana, Molina, Miguel A., Lopez-Martin, Jose Antonio, Berrocal, Alfonso
Published 2021Text